Loxosceles intermedia spider envenomation induces activation of an endogenous metalloproteinase, resulting in cleavage of glycophorins from the erythrocyte surface and facilitating complement-mediated lysis

Blood

Volumn 95, Issue 2, 2000, Pages 683-691

  Tambourgi, Denise V ^a   Morgan, B Paul ^b   De Andrade, Rute M G ^b   Magnoli, Fábio C ^b   Van Den Berg, Carmen W ^b  

^a INSTITUTO BUTANTAN   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; GLYCOPHORIN A; GLYCOPHORIN B; GLYCOPHORIN C; METALLOPROTEINASE; SPHINGOMYELIN PHOSPHODIESTERASE; SPIDER VENOM;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SPIDER;

EID: 0034650954     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.683     Document Type: Article

References (52)

1. Barreto CO, Cardoso JL, de Cillo D. Viscerocutaneous form of loxocelism and erythrocyte glucose-6-phosphate deficiency. Rev Inst Med Trop São Paulo. 1985;27:264.
2. Schenone H, Saavedra T, Rojas A, Villaroel F. Loxocelismo em Chile: estudios epidemiológicos, clinicos y experimentales. Rev Inst Med Trop São Paulo. 1989;31:403.
3. White J, Cardoso JL, Fan HW. Clinical toxinology of spider bites. In: Meier J, White J, eds. Handbook of Clinical Toxinology of Animal Venoms and Poisons. Boca Raton, FL: CRC Press; 1995:259.
4. Ginsburg CW, Weinberg AG. Hemolytic anemia and multiorgan failure associated with localized cutaneous lesion. J Pediatr. 1998;12:497.
5. Sezerino UM, Zannin M, Coelho LK, et al. A clinical and epidemiological study of Loxosceles spider envenoming in Santa Catarina, Brazil. Trans R Soc Trop Med Hyg. 1998;92:546.
6. Gendron BP. Loxosceles reclusa envenomation. Am J Emerg Med. 1990;8:51.
7. Futrell JM. Loxoscelism. Am J Med Sci. 1992; 304:261.
8. Bey TA, Walter FG, Lober W, Schmidt J, Spark R, Schlievert PM. Loxosceles arizonica bite associated with shock. Ann Emerg Med. 1997;30:701.
9. Tambourgi DV, Magnoli FC, von Eickstedt VRD, et al. Incorporation of a 35 kDa purified protein from Loxosceles intermedia spider venom transforms human erythrocytes into activators of autologous C alternative pathway. J Immunol. 1995; 155:4459.
10. Tambourgi DV, Magnoli FC, van den Berg CW, et al. Sphingomyelinases in the venom of the spider Loxosceles intermedia are responsible for both dermonecrosis and C-dependent haemolysis. Biochem Biophys Res Commun. 1998;251:366.
11. Tambourgi DV, Petricevich VL, Magnoli FC, Assaf SLMR, Jancar S, Dias da Silva W. The endotoxemic-like shock induced by Loxosceles spider venoms: pathological changes and putative cytokine mediators. Toxicon. 1998;36:391.
12. Morgan BP. C regulatory molecules: application to therapy and transplantation. Immunol Today. 1995;6:257.
13. Lachmann PJ. The control of homologous lysis. Immunol Today. 1991;12:312.
14. Rosse WF. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood. 1990;75:1595.
15. Wilcox LA, Ezzell JL, Bernshaw NJ, Parker CJ. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Blood. 1991;78:820.
16. Rosse WF, Parker CJ. Paroxysmal nocturnal haemoglobinuria. Clin Haematol. 1985;14:10.
17. Nakakuma H. Mechanism of intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). Am J Hematol. 1996;53:22.
18. Zaltzman AB, van den Berg CW, Muzykantov VR, Morgan BP. Enhanced C susceptibility of avidinbiotin-treated human erythrocytes is a consequence of neutralization of the C regulators CD59 and decay accelerating factor. Biochem J. 1995; 307:651.
19. Brauch H, Roelcke D, Rothe U. Glycophorin A inhibits lysis by the C attack phase. Immunobiology. 1983;165:115.
20. Tanner MJA. The major integral proteins of the human red cell. Baillieres Clin Haematol. 1993;6: 333.
21. Okada N, Yasuda T, Tsumita T, Shinomiya H, Utsumi S, Okada H. Regulation by glycophorin of C activation via the alternative pathway. Biochem Biophys Res Comm. 1982;108:770.
22. Parker CJ, Soldato CM, Telen MJ. Increased efficiency of binding of nascent C3b to erythrocytes of chronic cold agglutinin disease. J Clin Invest. 1984;74:1050.
23. Pangburn MK, Müller-Eberhard HJ. C3 convertase: cell surface restriction of β1 H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A. 1978;75: 2416.
24. Fearon D. Regulation by membrane sialic acid of β1H dissociation of amplification C3 convertase of the alternative C pathway. Proc Natl Acad Sci U S A. 1978;75:1971.
25. Okada N, Yasuda T, Tsumita T, Okada H. Activation of the alternative C pathway of guinea-gip by liposomes incorporated with trinitrophenylated phosphatidylethanolamine. Immunology. 1982; 45:115.
26. Reid ME, Lisowska E, Blanchard D. Coordinator's report: glycophorin/band 3 and associated antigens. Transfus Clin Biol. 1997;4:57.
27. Bucherl W. Biology and venoms of the most important South American spiders of the genera Phoneutria, Loxosceles, Lycosa and Latrodectus. Am Zool. 1969;9:157.
28. Lowry OH, Rosenbrough NJ, Farr AL, Randal RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265.
29. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680.
30. Morrisey JH. Silverstain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981;117:307.
31. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990;71:1.
32. Fletcher A, Bryant JA, Gardner B, et al. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology. 1992;75:507.
33. Ninomiya H, Abe T, Shichishima T, Terasawa T, Fujita T. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA). Br J Haematol. 1988;69:81.
34. Roberts WN, Wilson JG, Wong W, et al. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria. J Immunol. 1985;134:512.
35. Anstee DJ, Barker DM, Judson PA, Tanner MJ. Inherited sialoglycoprotein deficiencies in human erythrocytes of type En[a-]. Br J Haematol. 1977; 35:309.
36. Nash GB, Parmar J, Reid ME. Effects of deficiencies of glycophorins C and D on the physical properties of the red cell. Br J Haematol 1990;76: 282.
37. Tabbara IA. Hemolytic anemias: diagnosis and management. Med Clin North Am. 1992;76:649.
38. Gordjani N, Sutor AH, Zimmerhackl LB, Brandi M. Hemolytic uremic syndromes in childhood. Semin Thromb Hemost 1997;23:281.
39. Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am. 1995;42:1505.
40. Pichette V, Querin S, Schurch W, Brun G, Lehner-Netsch G, Delage JM. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis. 1994;24:936.
41. Seitz RC, Poschmann A, Hellwege HH. Monoclonal antibodies for the detection of desialylation of erythrocyte membranes during haemolytic disease and haemolytic uraemic syndrome caused by the in vivo action of microbial neuraminidase. Glycoconj J. 1997;14:699.
42. Arbus GS. Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome. Kidney Int Suppl. 1997;58:S91.
43. Lingwood CA, Law H, Richardson S, et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987;262:8834.
44. Bernheimer AW, Campbell BJ, Forrester LJ. Comparative toxinology of Loxosceles reclusa and Corynebacterium pseudotuberculosis. Science. 1985;226:590.
45. Hsu TY, Renshaw HW, Livingston CW Jr, Augustine JL, Zink DL, Gauer BB. Corynebacterium pseudotuberculosis exotoxin: fatal hemolytic anemia induced in gnotobiotic neonatal small ruminants by parenteral administration of preparations containing exotoxin. Am J Vet Res. 1985;46: 1206.
46. Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J. 197;321:265.
47. Turner AJ, Hooper NM. Role for ADAM-family proteinases as membrane protein secretases. Biochem Soc Trans. 1999;27:255.
48. Feitosa L, Gremski W, Veiga SS, et al. Detection and characterization of metalloproteinases with gelatinolytic, fibronectinolytic and fibrinogenolytic activities in brown spider (Loxosceles intermedia) venom. Toxicon. 1998;36:1039.
49. Gaczynska M, Bartosz G. Neutral serine proteinase and metalloproteinase strongly bound to human erythrocyte membrane. Cytobios. 1993;74: 29-33.
50. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997;11:355.
51. Khan MT, Wang K, Auland ME, Kable EP, Roufogalis BD. Membrane-bound high molecular mass proteinases from human erythrocytes. Biochim Biophys Acta. 1994;1209:215.
52. Rowe E, Welch RA. Assays of hemolytic toxins. Meth Enzymol. 1994;235:657.